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patients’ scores decreased 67.7% on HAMD-17 and 69.5% on
HAMD-7 (P < 0.05). Improvements in SNRI-treated patients
were similar (64.6% and 63.2%, respectively, P < 0.05). There
were no signiﬁcant differences between groups in response rates
(P = 0.45 for HAMD-17, 0.16 for HAMD-7). Per-protocol (PP)
remission rates measured using HAMD-17 at week 8 were
58.3% for SSRI-treated patients (N = 72) and 48.4% for SNRI-
treated patients (N = 64, P = 0.30). For the HAMD-7 group, PP
remissions were 40.4% for SSRIs (N = 57) and 44.4% for SNRIs
(N = 81, P = 0.73). Intent-to-treat (ITT) remission rates using
HAMD-17 were 46.7% for SSRI-treated patients (N = 90) and
39.2% for SNRI-treated patients (N = 79, P = 0.41). HAMD-7
ITT remission rates were 33.3% for SSRIs (N = 69) and 36.4%
for SNRIs (N = 99; P = 0.81). By 8 weeks, 18.9% dropped out
in the SSRI group and 18.5% in the SNRI group (P = 0.95).
CONCLUSIONS: Large, randomized, controlled, primary care
data are needed to adequately address the question of superior-
ity between SNRIs and SSRIs. Our post –hoc analysis found no
signiﬁcant differences between these two therapeutic groups. Suf-
ﬁciently powered studies comparing the effectiveness of antide-
pressant therapies in real-world settings are urgently needed.
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OBJECTIVES: Compare adults treated with SSRIs and SNRIs
for major depression. METHODS: Identiﬁed all head-to-head
trials comparing SSRIs (citalopram, escitalopram, ﬂuoxetine, ﬂu-
voxamine, paroxetine, sertraline) with SNRIs (venlafaxine-XR,
duloxetine) in therapeutic doses. Outcome: remission 12) at 8
weeks. Two reviewers searched £ 7 or MADRS £ 3 or HAMD-
17 £(HAMD-7 Medline, Embase and Cochrane databases to
identify articles, extract data, adjudicated by a third judge. Rates
were combined using random-effects meta-analytic model. Per-
formed Intent-to-Treat (ITT) and Per-Protocol (PP) 2 assessed
heterogeneity of effects. RESULTS: 25 studies were c analyses.
identiﬁed, 19 were rejected; 6 studies provided 7 head-to-head
trials of 1345 patients (68.0% females per drug). Five RCTs (N
= 1008) and 2 naturalistic trials (N = 337). All displayed non-
heterogeneity (P > 0.05). ITT Remission rates in RCTs: 49.5%
(SE = 6.2%, n = 398) for SNRIs; 39.3% (SE = 10.0%, n = 369)
for SSRIs; meta-analytic difference 9.2% (CI95%:
3.0%–15.4%). PP rates—67.8% (SE = 7.5%, n = 297) for
SNRIs; 56.5% (SE = 10.9%, n = 269) for SSRIs; meta-analytic
difference 9.8% (CI95%:0.2%–19.5%). Naturalistic studies
produced ITT rates of 37.6% (SE = 3.6%, n = 178) for SNRIs;
40.2% (SE = 6.7%, n = 159) for SSRIs; a non-signiﬁcant (P =
0.69) difference of 2.1% favoring SSRIs. PP rates 46.2% (SE =
4.1%, n = 145) for SNRIs; 49.6% (SE = 9.0%, n = 129) for
SSRIs; a difference of 2.9% (P = 0.68) favoring SSRIs. ITT remis-
sion rates were 46.2% (SE = 5.1%, n = 737) for SNRIs; 39.5%
(SE = 7.2%, n = 608) for SSRIs; meta-analytic difference of 6.5%
(CI95%: 0.2%–12.8%). PP rates were 61.8% (SE = 6.9%, n =
571) and 54.5% (SE = 8.1%, n = 450); meta-difference was
6.4% (P = 0.13). CONCLUSIONS: SNRIs seem more efﬁca-
cious. Naturalistic studies produced non-signiﬁcant results dif-
fering from RCT results.
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OBJECTIVES: To compare indirectly the efﬁcacy and safety of
duloxetine and venlafaxine-XR, the two currently available sero-
tonin-norepinephrine reuptake inhibitors (SNRIs) in treating
major depressive disorder. METHODS: Outcomes from pub-
lished, randomized, placebo-controlled trials reporting on mod-
erately-to-severely depressed patients [Hamilton Rating Scale for
Depression (HAM-D) ≥ 15]. A systematic literature search was
performed (1996–January 2005) on Cochrane, EMBASE and
MEDLINE databases. Two independent reviewers judged the
trials for acceptance. Last Observation Carried Forward (LOCF)
data were extracted. Differences in remission (8-week HAM-D
score £7), response (50% decrease on HAM-D), and dropout
rates from lack of efﬁcacy (LOE) and adverse events (AEs) were
meta-analyzed using a random effects model. Each rate was con-
trasted from placebo. RESULTS: Data were acquired from 8
trials from 1754 patients for efﬁcacy and 1791 patients for dis-
continuation/safety. Venlafaxine-XR rates were 17.8% (CI95%:
9.0%–26.5%) and 24.4% (CI95%: 15.0%–37.7%) greater than
placebo for remission and response, compared to 14.2%
(CI95%: 8.9%–26.5%) and 18.6% (CI95%: 13.0%–24.2%) for
duloxetine. Although numerically higher for venlafaxine-XR, no
statistically signiﬁcant differences were found between drugs,
however, both demonstrated overall remission and response rates
signiﬁcantly higher than placebo (p < 0.001). Dropout rates 
due to AEs were, contrasted with placebo, for venlafaxine-XR
6.1% (CI95%: 2.5%–9.7%) and for duloxetine 5.7% (CI95%:
1.5%–10.0%) greater than placebo. Dropout rates due to LOE
were for venlafaxine—XR 10.7% (CI95%: 6.4%–15.1%) and
for duloxetine 11.1% (CI95%: 6.3%–15.9%) less than placebo.
Again, when the two drugs were compared, no statistically sig-
niﬁcant difference was found for both dropout rates. Reported
adverse events were comparable between drugs. CONCLU-
SIONS: Venlafaxine-XR tends to have a favorable trend in remis-
sion and response rates compared to duloxetine, but for dropout
rates and AE these agents did not differ. A direct comparison is
warranted to conﬁrm this tendency.
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OBJECTIVES: To determine the cost effectiveness of a new 
reuptake inhibitor, when compared with -XR in treating major
depressive disorder. METHODS: A cost effectiveness analysis,
using a decision tree modeled outpatient treatment over six
months. Analytic perspectives were those of society (all direct
and indirect costs) and the Ministry of Health of as payer for all
direct costs. Rates of success and dropouts were obtained from
a meta-analysis of placebo-controlled trials. Costs were taken
from standard lists, adjusted to 2005 Canadian dollars; dis-
counting was not applied. One-way sensitivity analyses were 
performed on monthly acquisition costs and success rates;
Monte-Carlo analysis examined all parameters over 10,000 iter-
ations. RESULTS: From both perspectives, outcomes all numer-
ically-XR (Expected success = 53% and 57%, Symptom-free
A210 Abstracts
days 52.72 and 57.03 for uloxetine and venlafaxine-XR, respec-
tively). Total expected costs/patient treated were $7081 and
$6551, $20,987 and $19,997 (societal perspective), respectively.
Expected costs/SFD were $134 and $115 and $398 and $351
(societal viewpoint), respectively. Although results were sensitive
to changes in success rate within the 95% CI, Monte-Carlo
analyses using the ICER (incremental cost effectiveness ratio) as
outcome found -XR was dominant in approximately 78% of sce-
narios in both perspectives. CONCLUSIONS: Differences in
pharmacoeconomic outcomes found were modest, but in all
cases, favored venlafaxine-XR over duloxetine. Therefore, a pos-
sible advantage may exist at the population level in the treatment
of major depressive disorder in Canada. Ultimately, a head to
head study of the two drugs would be needed to conﬁrm these
ﬁndings.
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OBJECTIVES: To compare the cost-effectiveness of escitalopram
with venlafaxine and generic citalopram and in the ﬁrst-line
treatment of Major Depressive Disorder (MDD) in Germany.
METHODS: A two-path decision analytic model with a 6-month
horizon was adapted to the German setting using local clinical
guidelines and data. All patients (aged ≥ 18 years) started at the
primary care path and were referred to specialist care in the sec-
ondary care path in case of insufﬁcient response. Model inputs
included drug-speciﬁc probabilities derived from a meta-
analysis, clinical trials, published literature and expert opinion.
Costs are calculated on the basis of German ex-pharmacy price
for drugs, uniform remuneration scheme (EBM) for ambulatory
care and diagnosis related groups (DRG: U63Z) for secondary
care. Main outcome measures were success [Montgomery-
Åsberg-Depression-Rating-Scale (MADRS) £12] and costs of
treatment. The analysis was performed both from the German
Statutory Health Insurance (GKV) and the societal perspective.
The Human Capital approach was used to estimate the societal
costs. RESULTS: From both perspectives, treatment with esci-
talopram yielded lower expected cost and greater success of
treatment compared to generic citalopram. The expected success
rate for escitalopram was higher (61.7%) compared to generic
citalopram (57.7%). From the GKV perspective, the total
expected cost per successfully treated patient was €149 (17.7%)
lower for escitalopram (€694) compared to generic citalopram
(€843). From the societal perspective, the difference was €463
between expected costs of €1.717 and €2.180, respectively. Esc-
italopram demonstrated a similar treatment success to that of
venlafaxine at lower costs (€83 and €103, for GKV and societal
perspective, respectively). Multivariate sensitivity analyses
demonstrated the robustness of the results. In addition escitalo-
pram shows a similar cost-effectiveness-ratio even at costs of £0
for generic citalopram (€694 vs. €691). CONCLUSION: Esci-
talopram is a cost-effective alternative compared to generic
citalopram and venlafaxine in the ﬁrst-line treatment of MDD
in Germany.
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OBJECTIVES: The economic burden of affective disorders
(mood disorders) has become an important issue both for health
care providers as well as society as a whole. This study aims at
developing a model to estimating the cost of affective disorders
to the European society. METHODS: A model was developed,
based on the prevalence of the most prevalent affective disorders
(depression and bipolar disorders) and the cost per patient for
these disorders. The model served the following purposes: (1)
transform and convert available economic data to a deﬁned time
period as well as currency (€2004) (2) adjust country speciﬁc eco-
nomic data for purchasing power and relative size of economy
(3) impute data for countries where no data were available (4)
combine epidemiology and economic data to estimate the total
cost of affective disorders. The model was based on published
economic evidence in affective disorders in Europe, as well on
epidemiologic evidence from literature and databases. National
and international statistics for the model were retrieved from 
the Eurostat 2004 and OECD Health 2004 databases. The esti-
mates were presented in Euro for 2004. RESULTS: The total
number of adult people afﬂicted with affective disorders
amounted to 20.9 million in Europe. The cost of affective dis-
orders in Europe was estimated at €108.6 billion in 2004 prices.
The cost of depression only amounted to €91 billion, and bipolar
disorders to €31.6 billion. Indirect costs constituted 71% of the
total cost of affective disorders. Drug costs made up €7.2 billion
or 7% of the total cost. CONCLUSIONS: The cost of affective
disorders poses a signiﬁcant economic burden to European
society. The cost estimation model gives a reliable estimate of the
cost of illness in Europe based on the data and model algorithm
used.
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OBJECTIVE: to assess quality of life and quality of life changes
in subjects with major depression treated pharmacologically with
S-adenosyl-methyonine or imipramine. METHODS: This quality
of life assessment was a part of the MC3 trial, a short-term, mul-
ticentre, prospective, randomised, double blind, double placebo
controlled study of the anti-depressant effect of 42 days course
of oral SAMe 1600mg per day vs. oral imipramine 150mg per
day in subjects during a major depression episode. We used the
EuroQol instrument to evaluate QoL before (t0) and after treat-
ment (day 42). RESULTS: The analysis considered 238 patients
during a major depressive episode who completed the study
(72% female; mean age 45 +/- 12 years). Subjects had extremely
low comparable levels of overall QoL as measure through the
EQ-VAS (35.1 +/- 15 on average), which increased comparably
as an effect of treatment with either SAMe or imipramine (67
+/- 20). Several domains of QoL which where impaired before
treatment, improved afterwards, mainly anxiety and depression,
and ability to perform usual activities. EQ-VAS was only fairly
correlated with physician administered depression scales at the
start of treatment, while the correlation was good or very good
at the end of treatment. Self administered depression scales
showed a similar behavior as the EuroQol. CONCLUSION: Our
estimates show that the level of perceived overall QoL in sub-
jects with a major depressive episode is dramatically low. Phar-
macological treatment with SAMe or imipramine has a similar,
noticeable positive impact on QoL.
